(Q40233323)

18 September 2017

Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents (English)

1 reference

18 September 2017

Vasudevacharya Jayarama

1

1 reference

18 September 2017

Jennifer Marcello

2

1 reference

18 September 2017

Asa Ohagen

3

1 reference

18 September 2017

Veronica Gibaja

4

1 reference

18 September 2017

Douglas Lunderville

5

1 reference

18 September 2017

Jeff Horrigan

6

1 reference

18 September 2017

John Chapman

7

1 reference

18 September 2017

Aris Lazo

8

1 reference

18 September 2017

1 September 2006

1 reference

18 September 2017

1 reference

18 September 2017

46

1 reference

18 September 2017

9

1 reference

18 September 2017

1580-1588

1 reference

Investigation of CMV disease in immunocompromised patients

18 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

Betaherpesviruses in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

Summary of the II International Symposium on Cytomegalovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

Absence of activation of CMV by blood transfusion to HIV‐infected, CMV‐seropositive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

Pathogen inactivation of red cell concentrates using Inactine chemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

Development of a sensitive PCR inhibition method to demonstrate HBV nucleic acid inactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

Prevention of transfusion-acquired CMV infection: is there a role for NAT?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

CMV DNA is rarely detected in healthy blood donors using validated PCR assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2006.00926.X

10.1111/J.1537-2995.2006.00926.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference